Biotech Startups

Protomer develops dynamic medicines that modify their activity in the body to increase potency where and when needed. Founded by Caltech alumni and faculty, the company was acquired by Eli Lilly in 2021 and operates as a biotech subsidiary.

1 investor

ProTransit is developing Pro-MP, a patented sustained-release microparticle drug delivery platform that penetrates skin, scalp, eye, and mucosal tissues (and can be IV-administered) to deliver pharmaceutical active ingredients locally with minimal systemic uptake. Based on research from the University of Nebraska Medical Center, Creighton University, and USC Keck School of Medicine, the technology targets applications such as skin health and hair regrowth.

1 investor

Protyon develops personalized cancer therapies using computational modeling expertise. The company serves cancer patients and researchers in the biotech and healthcare industry.

1 investor

Provasctec develops a cell therapy combining mesenchymal stem cells with a biodegradable delivery device to create new vascular pathways, with a lead program targeting critical limb ischemia in peripheral artery disease patients. The company operates in regenerative medicine, applying biomaterial engineering and precision cell delivery to conditions including inflammation, cancer, and age-related diseases.

1 investor

Provepharm is a pharmaceutical company specializing in health-related dyes and colorants, committed to sustainable development and providing quality information on health products to medical professionals. The company operates internationally with French R&D expertise and is a UN Global Compact member.

1 investor

Proviera develops probiotic-based chemical treatments for leather manufacturing that reduce reliance on conventional chemicals while maintaining process efficiency. The products are designed for tanners and leather processors seeking sustainable alternatives with lower environmental impact.

1 investor

Provigate develops a low/non-invasive, low-cost home glucose monitoring service based on weekly glycated albumin (GA) testing from finger-prick blood or saliva samples via mail-in and point-of-care testing, paired with a coaching app and a remote monitoring dashboard for clinicians. It targets people with diabetes and those at risk, aiming to support behavior change for blood-sugar management.

1 investor

Proxygen discovers glue degraders, a novel drug modality that targets protein interactions for therapeutic treatments. The company uses protein science and molecular approaches to develop new treatments for disease.

1 investor

PSB Producción Vegetal breeds, develops, and distributes new stone fruit varieties through hybridization, trait selection, and climate-adaptation studies for growers and distributors. It focuses on R&D to improve fruit quality, yield, and disease resistance, holding over 130 patented varieties and producing around 40,000 new hybrids each year, serving national and international markets.

1 investor

Psigryph develops nanoparticle and nanofibre platform technologies to deliver nutrients and insoluble drug molecules into cells, with applications ranging from cancer therapeutics to consumer dietary supplements. It also offers biofertilizers, biopesticides, and phytonutrient-based health products.

1 investor

Psilox AB develops scientifically engineered biomaterials for dental health, including its CAPOSAL technology aimed at tooth mineralization and bone regeneration. The company applies expertise in the bioactivity and bioresorbability of ceramics to create material solutions for a range of dental products.

1 investor

Innovative drug discovery platform for the treatment of CNS disorders

1 investor

Cannasoul provides bioanalytical services supporting preclinical (non-GLP) and clinical (GCLP) studies, including analytical method development and validation for APIs and pharmaceuticals. It uses high-sensitivity LC-MS/MS (orbitrap) equipment to analyze study samples for pharmaceutical and research clients.

1 investor

PsyMed Ventures is a venture capital firm that invests in startups advancing brain and mental health through neuroscience and frontier technologies, including neurotech, brain-computer interfaces, digital health, precision neuroscience, and novel therapeutics. It backs founders working on neurotech, biotech, and digital health companies.

1 investor

Pulmotect develops immunomodulatory inhaled therapies designed to activate the lungs' innate immune system for preventing and treating respiratory complications in immunosuppressed patients and other high-risk populations. The company is advancing PUL-042, a patent-protected therapy being evaluated in clinical trials.

1 investor

Puma Biotechnology is a biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for cancer treatment. It runs clinical trials with the investigational drug alisertib for small cell lung cancer and metastatic breast cancer.

1 investor

Pumpkin is developing an all-natural, infant-safe additive that mothers can mix into pumped breast milk to preserve its freshness and nutrients during storage, along with tools to rapidly test breast milk nutritional quality. The company serves breastfeeding parents and lactation professionals through its breast milk science research.

1 investor

1 investor

Pure Algae develops land-based seaweed cultivation systems that capture nitrogen and CO2 from industrial fish farming and convert them into valuable biomass. The company serves aquaculture facilities seeking to add profitable revenue streams while reducing environmental impacts.

1 investor

Pure MHC discovers HLA Class I and Class II peptide targets for immunotherapies targeting cancer, infectious disease, and autoimmune diseases using the sHLA platform technology.

1 investor

Purgo Scientific develops localized drug delivery medical devices designed to deliver therapeutics to specific anatomical sites. The company serves clinical markets including orthopedic trauma and veterinary medicine, with commercialized veterinary products and human clinical development underway.

1 investor

Technologies for extracting, enriching, and quantifying nucleic acids (acquired).

1 investor

Purisys provides preclinical and early-phase development, manufacturing, reference standards, and small-scale GMP manufacturing for commercial active pharmaceutical ingredients (APIs). The company now operates as part of the Siegfried Group's Acceleration Hub following its acquisition.

1 investor

Purna provides contract development and manufacturing services for pharmaceutical projects, focusing on long-term customer partnerships and operational flexibility to meet customized client needs.

1 investor